AKT1 and head and neck squamous cell carcinoma: In this regard, multiple genomic alterations converging in the activation of the PI3K/AKT/mTOR pathway may explain the overeactivity of this signaling route in most HNSCC [19–21], which provided a rationale for multiple currently open clinical trials targeting PI3K, mTOR, as single agents and as part of combination therapies.